What is the reason Dr Reddy's has delayed commercial supplies of its semaglutide injection Obeda?

Dr Reddy's has delayed commercial supplies of semaglutide due to an issue related to the active pharmaceutical ingredient (API), where certain batches were found to be out of specification; the company is investigating the root cause and taking measures to ensure product quality.

Has the semaglutide supply issue affected patient safety or regulatory approvals for Dr Reddy's?

No, Dr Reddy's explicitly stated that there is no impact on patient safety or on the product's existing global regulatory filings.

Dr Reddy's delays semaglutide supply due to active ingredient issue

Jul 8, 2026

Dr Reddy's Laboratories delayed supplies of its semaglutide injection due to active ingredient specification issues, causing a 1.8% share price drop. The company confirmed no impact on patient safety while investigating the root cause amidst high demand for obesity treatments.

reuters

2026-07-08

Dr Reddy's delays semaglutide supply due to active ingredient issue

2026-09-17

Dr Reddy's signs India distribution deal for Takeda's Qdenga dengue vaccine

Dr Reddy's delays semaglutide supply due to active ingredient issue

FAQ